Finasteride is metabolized in the liver and excreted through urine and feces. Users humorously discuss its excretion, with one joking about it being expelled through ejaculation.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
The conversation is a satirical discussion about using grapefruit for hair regrowth, with suggestions ranging from injecting it to applying it topically or anally. Some users claim unusual benefits like emitting a green aura or jumping high.
The conversation discusses hair loss treatments, focusing on finasteride, minoxidil, and other options like PRP and ketoconazole. It highlights the importance of asking specific questions during a dermatology visit to determine the cause of hair loss and appropriate treatments.
RU58841 is used topically to prevent hair loss by blocking DHT, with suggestions to drink grapefruit juice, take breaks, avoid microneedling, and use lower concentrations to reduce side effects. Users discuss applying it at night to minimize systemic absorption.
A user speculates that a fast metabolism might affect the effectiveness of dutasteride for hair loss. Another user argues that drug response is unrelated to metabolism speed.
Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.
A user is organizing a group buy for various compounds aimed at reversing hair loss and gray hair, and improving brain health and fat loss. The user has developed a treatment plan based on extensive research and is inviting others to participate, with the option to choose only the compounds they need.
The conversation is about the potential dangers of taking oral minoxidil and grapefruit juice together. Some users express concern about dangerous drug interactions, while others argue that grapefruit juice may inhibit the metabolism of finasteride. The conclusion is that grapefruit juice may make finasteride less effective, but it won't affect minoxidil.
The conclusion of this conversation is that the user "DuckSeasonCamelSeasn" found that consuming grapefruit juice prior to taking finasteride or dutasteride helped them become a responder to the medications and regain hair growth. However, there are warnings about potential risks and interactions with other medications, so caution should be exercised.
The conversation is about managing allopregnanolone deficiency caused by 5-alpha-reductase inhibitors like finasteride or dutasteride. Specific treatments discussed for hair loss include Minoxidil, finasteride, and RU58841.
Liver problems may reduce the effectiveness of oral minoxidil due to impaired SULT1A1 enzyme activity, which is crucial for converting minoxidil to its active form. This reduction in enzyme function can significantly decrease the drug's effectiveness in promoting hair growth.
The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.
The user is considering using P5P to reduce high prolactin levels and is questioning if oral minoxidil could be contributing to the issue. They are also debating whether to switch from oral to topical minoxidil.
A 32-year-old male with diffuse thinning and seborrheic dermatitis has been using finasteride for 8 months without improvement. He is considering COQ10 + PQQ supplements for scalp inflammation and hair loss.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
The conversation discusses how different factors can stimulate type 1 and type 2 isoforms of 5-alpha reductase, which are enzymes linked to hair loss. Specific treatments mentioned include oral Dutasteride and topical Finasteride.
P5P supplementation helped reverse finasteride side effects, particularly by lowering prolactin levels and restoring sensitivity. The user experienced significant improvement within a day and full recovery in a few days.
PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.
Some people may not respond to topical minoxidil due to low SULT1A1 enzyme activity, but oral minoxidil can be effective. Tretinoin may enhance minoxidil's effectiveness, and some users prefer oral minoxidil despite side effects.
The user diagnosed with DUPA tried treatments like dutasteride, finasteride, RU58841, and minoxidil without success and is considering a hair system. They hope for a future cure, possibly with PP405, and others suggest options like scalp biopsy and SMP.
Elevated bile acids can inhibit the enzyme AKR1C2, leading to increased DHT levels, which may accelerate hair loss in those predisposed to androgenetic alopecia. Treatments mentioned include topical minoxidil and finasteride.
Tazarotene's potential to enhance Minoxidil conversion, similar to Tretinoin, is questioned. Users discuss the lack of information and seek further details.
Pumpkin Seed Oil and Perilla Oil (with alpha-lipoic acid, linoleic acid, and oleic acid) are discussed as potential 5alpha-reductase inhibitors. The conversation focuses on their effectiveness for hair loss treatment.
Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.
Minoxidil's effectiveness varies due to differences in sulfotransferase enzyme levels in the scalp, affecting people with conditions like ASD, liver disease, and androgenic alopecia. Treatments like topical tretinoin, microneedling, and using minoxidil sulfate instead of regular minoxidil can improve results for those with low enzyme levels.
New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.
Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.